CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers

被引:0
作者
L Kadouri
D F Easton
S Edwards
A Hubert
Z Kote-Jarai
B Glaser
F Durocher
D Abeliovich
T Peretz
R A Eeles
机构
[1] Sharett Institute of Oncology,Department of Endocrinology and Metabolism
[2] Hebrew University-Hadassah Medical Center,undefined
[3] CRC Section of Cancer Genetics,undefined
[4] The Institute of Cancer Research,undefined
[5] CRC Genetic Epidemiology Unit,undefined
[6] Strangeways Research Laboratories,undefined
[7] Hebrew University-Hadassah Medical Center,undefined
[8] Human Genetic Laboratories,undefined
[9] Hebrew University-Hadassah Medical Center,undefined
[10] The Royal Marsden NHS Trust,undefined
来源
British Journal of Cancer | 2001年 / 85卷
关键词
androgen receptor; polymorphisms; breast cancer risk;
D O I
暂无
中图分类号
学科分类号
摘要
Variation in the penetrance estimates for BRCA1 and BRCA2 mutations carriers suggests that other genetic polymorphisms may modify the cancer risk in carriers. A previous study has suggested that BRCA1 carriers with longer lengths of the CAG repeat in the androgen receptor (AR) gene are at increased risk of breast cancer (BC). We genotyped 188 BRCA1/2 carriers (122 affected and 66 unaffected with breast cancer), 158 of them of Ashkenazi origin, 166 BC cases without BRCA1/2 mutations and 156 Ashkenazi control individuals aged over 56 for the AR CAG and GGC repeats. In carriers, risk analyses were conducted using a variant of the log-rank test, assuming two sets of risk estimates in carriers: penetrance estimates based on the Breast Cancer Linkage Consortium (BCLC) studies of multiple case families, and lower estimates as suggested by population-based studies. We found no association of the CAG and GGC repeats with BC risk in either BRCA1/2 carriers or in the general population. Assuming BRCA1/2 penetrance estimates appropriate to the Ashkenazi population, the estimated RR per repeat adjusted for ethnic group (Ashkenazi and non-Ashkenazi) was 1.05 (95%CI 0.97–1.17) for BC and 1.00 (95%CI 0.83–1.20) for ovarian cancer (OC) for CAG repeats and 0.96 (95%CI 0.80–1.15) and 0.90 (95%CI 0.60–1.22) respectively for GGC repeats. The corresponding RR estimates for the unselected case–control series were 1.00 (95%CI 0.91–1.10) for the CAG and 1.05 (95%CI 0.90–1.22) for the GGC repeats. The estimated relative risk of BC in carriers associated with ≥28 CAG repeats was 1.08 (95%CI 0.45–2.61). Furthermore, no significant association was found if attention was restricted to the Ashkenazi carriers, or only to BRCA1 or BRCA2 carriers. We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak. © 2001 Cancer Research Campaign http://www.bjcancer.com
引用
收藏
页码:36 / 40
页数:4
相关论文
共 50 条
  • [31] Androgen receptor gene methylation and exon one CAG repeat length in ovarian cancer: Differences from breast cancer
    Kassim, SK
    Zoheiry, NM
    Hamed, WM
    Going, JJ
    Craft, JA
    IUBMB LIFE, 2004, 56 (07) : 417 - 426
  • [32] The CYP17A1 −34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Bella Kaufman
    Yael Laitman
    Elad Ziv
    Ute Hamann
    Diana Torres
    Ephrat Levy Lahad
    Rachel Beeri
    Paul Renbaum
    Anna Jakubowska
    Jan Lubinski
    Tomasz Huzarski
    Aleksandra Tołoczko-Grabarek
    Katarzyna Jaworska
    Katarzyna Durda
    Amanda B. Sprudle
    Georgia Chenevix-Trench
    Jacques Simard
    Douglas F. Easton
    Antoniou Antonis
    Csilla Szabo
    Eitan Friedman
    Breast Cancer Research and Treatment, 2011, 126 : 521 - 527
  • [33] The CYP17A1-34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Kaufman, Bella
    Laitman, Yael
    Ziv, Elad
    Hamann, Ute
    Torres, Diana
    Lahad, Ephrat Levy
    Beeri, Rachel
    Renbaum, Paul
    Jakubowska, Anna
    Lubinski, Jan
    Huzarski, Tomasz
    Toloczko-Grabarek, Aleksandra
    Jaworska, Katarzyna
    Durda, Katarzyna
    Sprudle, Amanda B.
    Chenevix-Trench, Georgia
    Simard, Jacques
    Easton, Douglas F.
    Antonis, Antoniou
    Szabo, Csilla
    Friedman, Eitan
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (02) : 521 - 527
  • [34] Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene
    Couch, FJ
    Weber, BL
    Borresen, AL
    Brody, L
    Casey, G
    Devilee, P
    Fitzgerald, M
    Friend, S
    Gayther, S
    Goldgar, D
    Murphy, P
    Szabo, C
    Weber, B
    Wiseman, R
    Anderson, T
    Durocher, F
    Ganguly, A
    King, MC
    Lenoir, G
    Narod, S
    Olopade, O
    Plummer, S
    Ponder, B
    Serova, O
    Simard, J
    Stratton, M
    Warren, B
    HUMAN MUTATION, 1996, 8 (01) : 8 - 18
  • [35] Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy
    Cohen, J. V.
    Chiel, L.
    Boghossian, L.
    Jones, M.
    Stopfer, J. E.
    Powers, J.
    Rebbeck, T. R.
    Nathanson, K. L.
    Domchek, S. M.
    FAMILIAL CANCER, 2012, 11 (01) : 69 - 75
  • [36] An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
    Georgia Chenevix-Trench
    Roger L Milne
    Antonis C Antoniou
    Fergus J Couch
    Douglas F Easton
    David E Goldgar
    Breast Cancer Research, 9
  • [37] The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers
    Catucci, Irene
    Verderio, Paolo
    Pizzamiglio, Sara
    Manoukian, Siranoush
    Peissel, Bernard
    Zaffaroni, Daniela
    Roversi, Gaia
    Ripamonti, Carla B.
    Pasini, Barbara
    Barile, Monica
    Viel, Alessandra
    Giannini, Giuseppe
    Papi, Laura
    Varesco, Liliana
    Martayan, Aline
    Riboni, Mirko
    Volorio, Sara
    Radice, Paolo
    Peterlongo, Paolo
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (03) : 855 - 860
  • [38] The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers
    Irene Catucci
    Paolo Verderio
    Sara Pizzamiglio
    Siranoush Manoukian
    Bernard Peissel
    Daniela Zaffaroni
    Gaia Roversi
    Carla B. Ripamonti
    Barbara Pasini
    Monica Barile
    Alessandra Viel
    Giuseppe Giannini
    Laura Papi
    Liliana Varesco
    Aline Martayan
    Mirko Riboni
    Sara Volorio
    Paolo Radice
    Paolo Peterlongo
    Breast Cancer Research and Treatment, 2011, 125 : 855 - 860
  • [39] Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Sean Brummel
    Yuan Chun Ding
    Christian F Singer
    Georg Pfeiler
    Henry T Lynch
    Katherine L Nathanson
    Timothy R Rebbeck
    Judy E Garber
    Fergus Couch
    Jeffrey Weitzel
    Steven A Narod
    Patricia A Ganz
    Mary B Daly
    Andrew K Godwin
    Claudine Isaacs
    Olufunmilayo I Olopade
    Gail Tomlinson
    Wendy S Rubinstein
    Nadine Tung
    Joanne L Blum
    Daniel L Gillen
    Breast Cancer Research, 11
  • [40] Androgen Receptor Gene CAG Repeat Polymorphism and Breast Cancer Risk in Iranian Women: A Case-Control Study
    Mehdipour, Parvin
    Pirouzpanah, Saeed
    Kheirollahi, Majid
    Atri, Morteza
    BREAST JOURNAL, 2011, 17 (01) : 39 - 46